XML 94 R50.htm IDEA: XBRL DOCUMENT
v3.22.4

List of principal companies included in the scope of consolidation during 2022 | 12 Months Ended
--- | ---
Dec. 31, 2022
Interests In Other Entities [Abstract] |
List of principal companies included in the scope of consolidation during 2022 | List of principal companies included in the scope of consolidation during 2022 F.1. Principal fully consolidated companies The table below shows Sanofi's principal subsidiaries and their country of incorporation:
Europe |  | Financial interest (%) as of December 31, 2022
Hoechst GmbH | Germany | 100.0 |
Sanofi-Aventis Deutschland GmbH | Germany | 100.0 |
A. Nattermann & Cie. GmbH | Germany | 100.0 |
Sanofi-Aventis GmbH | Austria | 100.0 |
Sanofi Belgium | Belgium | 100.0 |
Ablynx N.V. | Belgium | 100.0 |
Genzyme Flanders BVBA | Belgium | 100.0 |
Sanofi A/S | Denmark | 100.0 |
Sanofi-Aventis S.A. | Spain | 100.0 |
Opella Healthcare Spain, S.L. | Spain | 100.0 |
Sanofi Oy | Finland | 100.0 |
Sanofi | France | 100.0 |
Sanofi-Aventis France | France | 100.0 |
Sanofi Winthrop Industrie | France | 100.0 |
Sanofi-Aventis Recherche & Développement | France | 100.0 |
Sanofi-Aventis Groupe | France | 100.0 |
Sanofi Chimie | France | 100.0 |
Sanofi-Aventis Participations | France | 100.0 |
Sanofi Pasteur | France | 100.0 |
Aventis Pharma S.A. | France | 100.0 |
Sanofi Biotechnology | France | 100.0 |
Sanofi Mature IP | France | 100.0 |
Sanofi Pasteur NVL | France | 100.0 |
Sanofi Pasteur Europe | France | 100.0 |
SECIPE SAS | France | 100.0 |
Sanofi Pasteur Merieux S.A.S. | France | 100.0 |
Sanofi 2015 D SAS | France | 100.0 |
Opella Healthcare International SAS | France | 100.0 |
Opella Healthcare France SAS | France | 100.0 |
Opella Healthcare Group SAS | France | 100.0 |
Sanofi-Aventis A.E.B.E. | Greece | 100.0 |
Sanofi-Aventis Private Co, Ltd | Hungary | 99.6 |
Chinoin Private Co. Ltd | Hungary | 99.6 |
Opella Healthcare Hungary Commercial K.F.T | Hungary | 100.0 |
Carraig Insurance DAC | Ireland | 100.0 |
Genzyme Ireland Limited | Ireland | 100.0 |
Sanofi-Aventis Holdings (Ireland) Ltd | Ireland | 100.0 |
Sanofi S.R.L. | Italy | 100.0 |
Opella Healthcare Italy S.R.L. | Italy | 100.0 |
Genzyme Global Sarl | Luxembourg | 100.0 |
Genzyme Luxembourg Sarl | Luxembourg | 100.0 |
Sanofi-Aventis Norge AS | Norway | 100.0 |
Genzyme Europe B.V. | Netherlands | 100.0 |
Sanofi Foreign Participations B.V. | Netherlands | 100.0 |
Sanofi-Aventis Sp. z.o.o. | Poland | 100.0 |
Opella Healthcare Poland sp.Z.O.O | Poland | 100.0 |
Sanofi Pasteur Sp. z.o.o. | Poland | 100.0 |
Sanofi Produtos Farmaceuticos Lda | Portugal | 100.0 |
Sanofi-Aventis, s.r.o. | Czech Republic | 100.0 |
Opella Healthcare Czech s.r.o | Czech Republic | 100.0 |
Sanofi Romania SRL | Romania | 100.0 |
Europe |  | Financial interest (%) as of December 31, 2022
Opella Healthcare Romania S.R.L. | Romania | 100.0 |
Sanofi-Aventis UK Holdings Limited | United Kingdom | 100.0 |
Aventis Pharma Limited | United Kingdom | 100.0 |
Sanofi-Synthelabo UK Ltd | United Kingdom | 100.0 |
Aventis Pharma Holdings Ltd | United Kingdom | 100.0 |
Opella Healthcare UK Limited | United Kingdom | 100.0 |
AO Sanofi Russia | Russia | 100.0 |
Opella Healthcare LLC | Russia | 100.0 |
Sanofi AB | Sweden | 100.0 |
Sanofi-Aventis (Suisse) SA | Switzerland | 100.0 |
Genzyme Global Sarl Baar Intellectual Property Branch | Switzerland | 100.0 |
Sanofi Ilac Sanayi ve Ticaret A.S. | Turkey | 100.0 |
Sanofi Pasteur Asi Ticaret A.S. | Turkey | 100.0 |
Sanofi Saglik Urunleri Limited Sirketi | Turkey | 100.0 |
United States |  | Financial interest (%) as of December 31, 2022
Genzyme Therapeutic Products Limited Partnership | United States | 100.0 |
Aventis Inc. | United States | 100.0 |
Sanofi US Services Inc. | United States | 100.0 |
Sanofi-Aventis U.S. LLC | United States | 100.0 |
Chattem, Inc. | United States | 100.0 |
Aventisub LLC | United States | 100.0 |
Genzyme Corporation | United States | 100.0 |
Sanofi Pasteur Inc. | United States | 100.0 |
VaxServe, Inc. | United States | 100.0 |
Bioverativ Inc. | United States | 100.0 |
Bioverativ U.S. LLC | United States | 100.0 |
Bioverativ Therapeutics Inc. | United States | 100.0 |
Principia Biopharma Inc. | United States | 100.0 |
Sanofi Research Invest LLC | United States | 100.0 |
Sanofi Bioverativ Holdings LLC | United States | 100.0 |
RPR US Ltd. | United States | 100.0 |
Kadmon Holdings, Inc. | United States | 100.0 |
Kadmon Corporation, LLC | United States | 100.0 |
Amunix | United States | 100.0 |
Synthorx, Inc | United States | 100.0 |
Translate Bio, Inc | United States | 100.0 |
Other Countries |  | Financial interest (%) as of December 31, 2022
Sanofi-Aventis South Africa (Pty) Ltd | South Africa | 100.0 |
Sanofi-Aventis Algérie | Algeria | 100.0 |
Sanofi Arabia Trading Company Limited | Saudi Arabia | 75.0 |
Sanofi-Aventis Argentina S.A. | Argentina | 100.0 |
Genzyme de Argentina S.A. | Argentina | 100.0 |
Opella Healthcare Argentina S.A.U. | Argentina | 100.0 |
Sanofi-Aventis Healthcare Pty Ltd | Australia | 100.0 |
Sanofi-Aventis Australia Pty Ltd | Australia | 100.0 |
Sanofi Medley Farmaceutica Ltda | Brazil | 100.0 |
Sanofi-Aventis Canada Inc. | Canada | 100.0 |
Sanofi Pasteur Limited | Canada | 100.0 |
Merieux Canada Holdings ULC (Canada) | Canada | 100.0 |
Sanofi-Aventis de Chile S.A. | Chile | 100.0 |
Sanofi (Hangzhou) Pharmaceuticals Co., Ltd | China | 100.0 |
Sanofi (China) Investment Co., Ltd | China | 100.0 |
Sanofi (Beijing) Pharmaceuticals Co.Ltd | China | 100.0 |
Sanofi Pasteur Biologies Co., Ltd | China | 100.0 |
Shenzhen Sanofi pasteur Biological Products Co, Ltd | China | 100.0 |
Shanghai Rongheng Pharmaceutical Co, Ltd | China | 100.0 |
Genfar S.A. | Colombia | 100.0 |
Sanofi-Aventis de Colombia S.A. | Colombia | 100.0 |
Sanofi-Aventis Korea Co. Ltd | South Korea | 100.0 |
Sanofi Pasteur Ltd | South Korea | 100.0 |
Opella healthcare Korea Inc. | South Korea | 100.0 |
Sanofi-Aventis Gulf FZE | United Arab Emirates | 100.0 |
Sanofi Egypt | Egypt | 99.8 |
Opella Healthcare Egypt LLC | Egypt | 100.0 |
Sanofi Hong-Kong Limited | Hong Kong | 100.0 |
Sanofi India Limited | India | 60.4 |
Sanofi Healthcare India Private Limited | India | 99.9 |
Sanofi-Aventis Israël Ltd | Israel | 100.0 |
Sanofi K.K. | Japan | 100.0 |
SSP Co.,Ltd | Japan | 100.0 |
Sanofi-Aventis (Malaysia) SDN. BHD. | Malaysia | 100.0 |
Sanofi-Aventis Maroc | Morocco | 100.0 |
Sanofi-Aventis de Mexico S.A. de C.V. | Mexico | 100.0 |
Sanofi Pasteur S.A. de C.V. | Mexico | 100.0 |
Azteca Vacunas, S.A. de C.V. | Mexico | 100.0 |
Sanofi-Aventis Pakistan Limited | Pakistan | 52.9 |
Sanofi-Aventis de Panama S.A. | Panama | 100.0 |
Sanofi-Aventis del Peru S.A. | Peru | 100.0 |
Sanofi-Aventis Puerto Rico Inc | Puerto Rico | 100.0 |
Sanofi-Aventis Philippines Inc. | Philippines | 100.0 |
Opella Healthcare Philippines Inc. | Philippines | 100.0 |
Sanofi-Aventis Singapore Pte. Ltd | Singapore | 100.0 |
Aventis Pharma (Manufacturing) Pte. Ltd | Singapore | 100.0 |
Sanofi Manufacturing Pte Ltd | Singapore | 100.0 |
Sanofi Taiwan Co., Ltd | Taiwan | 100.0 |
Sanofi-Aventis (Thailand) Ltd | Thailand | 100.0 |
Sanofi-Aventis de Venezuela S.A. | Venezuela | 100.0 |
Sanofi-Aventis Vietnam Company Limited | Vietnam | 100.0 |
Sanofi Vietnam Shareholding Company Limited | Vietnam | 85.0 |
F.2. Principal investments accounted for using the equity method
|  | Financial interest (%) as of December 31, 2022
GlaxoSmithKline Consumer Healthcare, L.P. | United States | 11.7 |
Infraserv GmbH & Co. Höchst KG | Germany | 31.2 |
Maphar | Morocco | 48.3 |
MCM Vaccine B.V. | Netherlands | 50.0 |
MSP Vaccine Company (formerly MCM company) | United States | 50.0 |
EUROAPI | France | 30.1 |

X
- Definition The disclosure of subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2021-01-01 -Paragraph 17 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2021-01-01 -Paragraph 16 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph B4 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Interests In Other Entities [Abstract] + References No definition available. + Details
Name: | sny_InterestsInOtherEntitiesAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration